 |
|
|
|
|
| |
|
Company Overview
Constellation
Pharmaceuticals is the leading biopharmaceutical company
dedicated to the development of novel therapeutics in
the emerging field of epigenetics, a new field of
biology that involves chemical modifications of DNA and
its packaging proteins, which collectively are called
the ‘epigenome.’
As the genome captured the interest and imagination of
the scientific community to identify new, breakthrough
therapeutics, the epigenome provides an entirely new
class of targets for the development of novel therapeutics with the potential to dramatically improve
the way diseases are treated.
The genome, or DNA, is the “blueprint” for the human
body, consisting of thousands of genes, which are the
fundamental units of information necessary for normal
cell growth and development. The epigenome plays a
critical role in regulating the expression of genes,
that is, switching genes on or off – or in the case of
disease, for switching genes on or off incorrectly.
Because mis-regulation of gene expression can occur
without mutations in the underlying DNA sequence of the
gene expressed, the epigenome is critical for the
development of organisms, as well as disease. This new
field of science provides the opportunity to
create a broad class of human therapeutics targeting
selective regulators of epigenetic function.
As an example, in the case of oncology, one role of
tumor suppressor genes is to ensure that abnormal cells
die through apoptosis. If the tumor suppressor gene is
not expressed – due to incorrect epigenetic regulation
-- this process cannot occur and the abnormal cells
continue to develop and metastasize. This is one example
of how epigenetics represents a fertile field for
research and provides significant opportunities for
discovering improved treatments in many diseases.
Constellation’s scientific founders represent the core
thought leaders in epigenetics, responsible
for key advances, insights and discoveries in the
burgeoning field. Their deep scientific insights will
help drive the Company’s success and mission.
Constellation is pursuing multiple avenues to achieve
leadership in epigenetics. The Company is building a
technology platform to expeditiously and simultaneously
explore multiple targets in multiple therapeutic areas.
Constellation will leverage this platform to build a
deep and diversified product pipeline of small molecules
designed to modulate the epigenetic changes responsible
for disease.

About our name
The definition of ‘constellation’ is: “any
brilliant, outstanding group or assemblage.” We chose
this name to highlight the stellar alignment of
scientific and business talent that is represented
within Constellation Pharmaceuticals, an unprecedented
gathering of the core thought leaders in the field of epigenetics.
|
|
|
|